Trial to Assess the Safety and Clinical Performance of Contino® in Preventing Urinary Incontinence

  • days left to enroll
  • participants needed
  • sponsor
    CMX Research
Updated on 22 March 2022


This trial is to assess the safety and clinical performance of Contino device is preventing Urinary Incontinence in male subjects with Sphincteric Incompetence


Sphincteric incompetence is most commonly found in men who have had radical prostatectomy (RP). RP is the most common treatment for localized high-risk Prostate Cancer in North America.

The Contino®, a urethral insert, was conceived by a prostate cancer survivor and worn for 10+ years without incident, and a First in Human clinical trial was completed without serious adverse event. The basis for this clinical trial is a post market clinical follow-up study. No drug treatment will be administered.

Condition Urinary Incontinence
Treatment Contino
Clinical Study IdentifierNCT04165408
SponsorCMX Research
Last Modified on22 March 2022


Yes No Not Sure

Inclusion Criteria

Male 18 years of age or older
Evidence of sphincteric incompetence as assessed by the Investigator
ECOG 0 or 1 performance status
Evidence of moderate to severe urinary incontinence as assessed by the Investigator, typically 2 or more protective garments or pads per day

Exclusion Criteria

Inability to consistently insert the Contino® into his own urethra and remove it
Less than 2 months post radical prostatectomy for localized prostate cancer
History of significant incontinence that is other than stress incontinence
Evidence of neurogenic bladder dysfunction resulting in uncontrolled contractions
Untreated urethral stricture disease
Use of anticoagulant or antiplatelet medications excluding low-dose ASA (in the opinion of the Investigator)
Any cardiac condition that requires the use of pre-procedure antibiotic prophylaxis such as a mechanical valve (in the opinion of the Investigator)
Body Mass Index (BMI) greater than 32 kg/m2 (in the opinion of the Investigator provided the subject is able to insert & remove the device)
Known immune deficiency either due to disease or medications (in the opinion of the Investigator)
Uncontrolled diabetes (in the opinion of the Investigator)
An UTI (in the opinion of the Investigator)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note